{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jimenez-Alesanco A"],"funding":["Instituto de Salud Carlos III","Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas","Ministerio de Ciencia e Innovación","Fundació la Marató de TV3","European Commission","Secretaría de Estado de Investigación, Desarrollo e Innovación","Gobierno de Aragón"],"pagination":["e4427"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9514063"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["31(10)"],"pubmed_abstract":["Bacteroides fragilis is an abundant commensal component of the healthy human colon. However, under dysbiotic conditions, enterotoxigenic B. fragilis (ETBF) may arise and elicit diarrhea, anaerobic bacteremia, inflammatory bowel disease, and colorectal cancer. Most worrisome, ETBF is resistant to many disparate antibiotics. ETBF's only recognized specific virulence factor is a zinc-dependent metallopeptidase (MP) called B. fragilis toxin (BFT) or fragilysin, which damages the intestinal mucosa and triggers disease-related signaling mechanisms. Thus, therapeutic targeting of BFT is expected to limit ETBF pathogenicity and improve the prognosis for patients. We focused on one of the naturally occurring BFT isoforms, BFT-3, and managed to repurpose several approved drugs as BFT-3 inhibitors th"],"journal":["Protein science : a publication of the Protein Society"],"pubmed_title":["Repositioning small molecule drugs as allosteric inhibitors of the BFT-3 toxin from enterotoxigenic Bacteroides fragilis."],"pmcid":["PMC9514063"],"funding_grant_id":["PID2019‐107725RG‐I00","201815","PI18/00349","PI21/00394","CPII13/00017","E25_20R","E45_20R","BFU2016‐78232‐P"],"pubmed_authors":["Abian O","Asencio Del Rio M","Guevara T","Gomis-Ruth FX","Eckhard U","Jimenez-Alesanco A","Vega S","Velazquez-Campoy A"],"additional_accession":[]},"is_claimable":false,"name":"Repositioning small molecule drugs as allosteric inhibitors of the BFT-3 toxin from enterotoxigenic Bacteroides fragilis.","description":"Bacteroides fragilis is an abundant commensal component of the healthy human colon. However, under dysbiotic conditions, enterotoxigenic B. fragilis (ETBF) may arise and elicit diarrhea, anaerobic bacteremia, inflammatory bowel disease, and colorectal cancer. Most worrisome, ETBF is resistant to many disparate antibiotics. ETBF's only recognized specific virulence factor is a zinc-dependent metallopeptidase (MP) called B. fragilis toxin (BFT) or fragilysin, which damages the intestinal mucosa and triggers disease-related signaling mechanisms. Thus, therapeutic targeting of BFT is expected to limit ETBF pathogenicity and improve the prognosis for patients. We focused on one of the naturally occurring BFT isoforms, BFT-3, and managed to repurpose several approved drugs as BFT-3 inhibitors th","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2026-05-31T02:13:39.88Z","creation":"2025-02-19T01:22:16.946Z"},"accession":"S-EPMC9514063","cross_references":{"pubmed":["36173175"],"doi":["10.1002/pro.4427"]}}